

PCT

REC'D 0 9 OCT 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant	or 20	ont's file reference	Ţ							
Applicant's or agent's file reference PSX004wo			FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/4							
		Ecotion No.	International filing data (de	/anth/		, ,				
International application No. PCT/CH99/00289			International filing date (da 02/07/1999	ay/monu v	year)	Priority date (day/month/yell 02/07/1999	ar)			
International Patent Classification (IPC) or national classification						02/07/1999				
A61K31		ent Classification (IFC) of fla	monal classification and IPC							
Applicant					-					
SCA LO	HNH	ERSTELLUNGS AG e	t al.				<u>,, </u>			
	The state of the s									
and i	s tran	smitted to the applicant a	according to Article 36.							
0 75	DED4	NDT								
2. Inis	2. This REPORT consists of a total of 5 sheets, including this cover sheet.									
	This re	eport is also accompanie	d by ANNEXES, i.e. shee	ts of the	description	n, claims and/or drawings	which have			
t	een a	amended and are the bas	sis for this report and/or s	heets co	ntaining red	ctifications made before th				
,	see r	rule 70.16 and Section 60	07 of the Administrative Ir	istructio	ns under th	e PCT).				
Thes	e ann	exes consist of a total of	sheets.			*				
3. This	report	contains indications rela	ting to the following items	s:						
	⊠									
J FI		Basis of the report Priority								
		•	pinion with regard to nove	elty inve	entive sten a	and industrial applicability				
IV				only, mive	antive Step t	and modelinal applicability				
٧	_									
VI		Certain documents cite		ient						
VII		Certain defects in the international application								
VIII			s on the international application							
Date of sub	missio	on of the demand		Data of or	empletion of t	his roport				
Date 01 501	,,,,,,,,,,,	or the demand] '	Date of CC	impleation of t	rus report				
02/02/2001				08.10.200)1					
		g address of the international ining authority:	1	Authorized officer						
		pean Patent Office								
<i>)</i>)))298 Munich +40 89 2309 - 0. Tv: 523656	opmu d	Doming	ues, H					
		+49 89 2399 - 4465		Felephona Felephona	No. +49 89	2399 7810	SONIS DING. ENECYPO			
<u></u>		+49 89 2399 - 0 Tx: 523656 +49 89 2399 - 4465	epmu d	_		0200 7040	THE TOWN THE TOWN			
			1 1		・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・	EU00 / U I U				

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CH99/00289

I.	Bas	sis of the report										
1.	With regard to the elements of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)): Description, pages:											
	1-1	0 a	s originally filed									
			<u>-</u> ,									
	Cla	Claims, No.:										
	1-1-	4 a	s originally filed									
2.	With regard to the language , all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.											
	The	ese elements were av	ailable or furnished to the	s Authority in the following	language:	, which is:						
		the language of a tra	anslation furnished for th	e purposes of the internatio	nal search ((under Rule 23.1(b)).						
	☐ the language of publication of the international application (under Rule 48.3(b)).											
		the language of a translation furnished for the purposes of international preliminary examination (under Rul 55.2 and/or 55.3).										
3.		With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:										
		contained in the inte	rnational application in w	ritten form.								
(☐ furnished subsequently to this Authority in computer readable form.										
		☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.										
4.	The	amendments have r	esulted in the cancellatio	n of:								
		the description,	pages:									
		the claims,	Nos.:									
		the drawings,	sheets:									

5.

This report has been established as if (some of) the amendments had not been made, since they have been

considered to go beyond the disclosure as filed (Rule 70.2(c)):



International application No. PCT/CH99/00289

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

- 6. Additional observations, if necessary:
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes: No:

Claims

Claims 1-14 Yes

Inventive step (IS)

Yes:

Claims

No:

Claims 1-14 No

Industrial applicability (IA)

Yes:

Claims

No: Claims 1-14 yes

2. Citations and explanations see separate sheet

1. Subject-matter of the application

The application discloses a solid formulation of glucosamine sulphate or a mixed salt thereof that is comprised in an effervescent drinkable preparation. Said preparation should contain the necessary daily dose of glucosamine. It should also comprise carbonate or bicarbonate salts and a fruit acid, preferably, crystalline citric acid, to enhance stability, prevent oxidation and help in the release of the carbon dioxide when the preparation is dissolved in water. Other additives, like colorants and flavors, can also be present in the preparation. According to the description, solid glucosamine sulpahte is rather unstable because it is highly hygroscopic and its amino group oxidises easily. The main advantage of the present invention over the prior art is that it provides a storage-stable drinkable formulation that only needs to be administered once a day since it contains a one-day-dose.

2. Concerning section V

The examination was carried out under the assumption that the priority is valid and was based on the following prior art documents cited in the International Search Report:

- D1: PATENT ABSTRACTS OF JAPAN vol. 1999, no. 09, 30 July 1999 (1999-07-30) & JP 011 092385 A (KOYO CHEM. KK,JP), 6 April 1999 (1999-04-06)
- D2: US-A-3 683 076 (L. ROVATI (MI,IT)) 8 August 1972 (1972-08-08) cited in the application
- D3: US-A-4 642 340 (P. SENIN ET AL. (MI,IT)) 10 February 1987 (1987-02-10) cited in the application
- D4: EP-A-0 444 000 (HEALTH MAINTENANCE PROGRAMS INC.,U.S.A.) 28 August 1991 (1991-08-28) cited in the application

i) Inventive Step, Art. 33(3)PCT

Claim 1 is directed to an effervescent preparation of glucosamine sulphate or mixed salts thereof. Document D1 refers to a drinkable preparation of glucosamine salt, like glucosamine hydrochloride, that is stable even in the form of a liquid. The therepeutic and pharmacological properties of glucosamine seem to be preserved in such a preparation since it is said to be useful for the treatment of arthropathy. The described preparation also contains an organic acid that may be hydroxilated and a saccharide.

WRITTEN OPINION SEPARATE SHEET

Document D1 is the closest prior art and the difference between this document and the present application is that in former glucosamine hydrochloride is used whereas in the latter glucosamine sulphate or mixed salts (according to the description, pg. 8, glucosamine KCl or glucosamine HCl) are used. Therefore, the underlying technical problem is to obtain an effervescent (drinkable) preparation of glucosamine sulphate or mixed KCl and HCl salts of said compound. This is achieved by the invention by using said glucosamine compounds, a fruit acid, a carbonate or bicarbonate and other additives according to example 1. Methods for the preparation of glucosamine sulphate are known from the prior art (D2, column 1-3; D4, column 4, line 15-23) and, according to the description, pg. 2, the formation of mixed salts of glucosamine sulphate with sodium and potassium chloride has also been described (see also D3). Furthermore, the oral dosage forms of glucosamine sulphate disclosed in D4 contain the essential components of the effervescent preparation of claim 1: glucosamine sulphate, a fruit acid and a carbonate (see column 8).

In view of the disclosures above, it is the opinion of the examining division that the skilled in the art, when faced with the above mentioned technical problem, would combine the teachings in D1 with those in D2, D3 and D4 and arrive at the solution proposed by the invention without the need of inventive activity. Therefore, inventive step as set out in Art. 33(3)PCT cannot be acknowledge for claim 1 and the dependant claims 2-13. Moreover, since claim 14 is a product-by-process claim it also lacks inventive step under Art. 33(3)PCT due to the above cited reasons.